Bhavana Konda

机构：The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University · ORCID：0000-0002-9099-5990

发表论文 170 篇 · 总被引 2885 次 · h-index 23

代表论文

• Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors (2024 · New England Journal of Medicine · 被引 158)
• Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement (2025 · The Lancet Diabetes & Endocrinology · 被引 41)
• Inhibition of Bruton’s tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors (2024 · JCI Insight · 被引 8)
• Whole-Exome Sequencing Reveals High Prevalence of Germline Alterations in Neuroendocrine Neoplasms (2025 · Journal of the National Comprehensive Cancer Network · 被引 5)
• Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort (2025 · Journal for ImmunoTherapy of Cancer · 被引 5)
• Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602). (2025 · Journal of Clinical Oncology · 被引 4)